Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
ABVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.77 - $97.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)1.07M
Market Cap
$7.16B
Enterprise Value$513.05M
Total Cash (Recent Filing)$60.95M
Total Debt (Recent Filing)$98.71M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Dec 15, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding77,828,920
10 Day Avg. Volume1,189,521
30 Day Avg. Volume1,070,577
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.98
Price to Sales (P/S)41.30
P/FCF Ratio-2.88
Enterprise Value/Market Cap0.07
Enterprise Value/Revenue54.49
Enterprise Value/Gross Profit54.49
Enterprise Value/Ebitda-2.27
Forecast
1Y Price Target
$121.25Price Target Upside29.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive topline induction results from the Phase 3 ABTECT program for lead program obefazimod in ulcerative colitis.
Debt ManagementAbivax no longer holds any debt with Heights Capital Management.
Drug EfficacyObefazimod shows robust activity in advanced treatment refractory ulcerative colitis, confirming its potential for broad use across the treatment paradigm.
Market AdoptionObefazimod's oral route of administration and efficacy across therapy lines, without the safety concerns of JAK inhibitors, supports broad adoption in UC.
Bears Say
Competitive LandscapeA placebo-adjusted clinical remission rate of 10% or greater during induction would be considered favorable for the AT-experienced population versus many of the currently approved treatments.
Financial StabilityAnnualized cash burn is $205.0 million with the company having approximately 2.5 years of cash left.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $97.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $7.16B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Dec 15, 2025 which is in 61 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Sep 08, 2025. The company reported -$1.376 earnings per share for the quarter, missing the consensus estimate of -$0.929 by -$0.447.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.73.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 77,828,920 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$1.376 in its last earnings report, missing expectations of -$0.929. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.25 (29.31% Upside)
$121.25 (29.31% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 18.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
945.37%
12-Months-Change
Fundamentals
Return on Equity
-147.48%
Trailing 12-Months
Asset Growth
-41.18%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$121.25
▲(29.31% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
―
Insiders
0.69% Mutual Funds
32.33% Other Institutional Investors
66.91% Public Companies and
Individual Investors